High throughput process development is a platform that is used to reduce the development and processing time of various biological and biomedical processes. This is widely deployed by biotechnology and pharmaceutical industries due to its several advanatages such as robust and scalable processing, time saver, highly efficient etc. The global high throughput process development market is expected to grow at a CAGR of 15% during the forecast period.

North America is the leading market region for high throughput process development market and had for accounted for the largest market revenue share in 2016. The key factors boosting the growth of global high throughput process development market in North America region is the rising expenditure on R&D infrastructure by the pharmaceutical and biopharmaceutical industries. Moreover, there is increasing demand for technologically advanced tools to enhance the production quality of biological materials in North America. Furthermore, the presence of major biotechnology and pharmaceutical industries in United States are driving the market growth. Asia-Pacific region is anticipated to be the fasting growing market region and is expected to grow at the highest CAGR during the forecast period 2016-2023. The key factors owing to this growth are the increasing governmental financial support in developing APAC countries such as India, Japan and China etc. The increased adoption of high throughput process development tools is driving the market growth in Asia Pacific region.

The global high throughput process development market is influenced by the presence of leading biotech and pharmaceutical companies such as Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Merck Millipore, Agilent technologies Inc. etc. Product launch, joint ventures, merger and acquisition are some of the crucial strategies adopted by the key market players to gain competitive advantage.

Global high throughput process development market report covers segmentation analysis of products and services, molecule type, process type and end user. Report further covers segments of products and services which include consumables & reagents, instruments and software & services. The software and services is the leading segment due to the increased adoption of high throughput process development tools and software in order to facilitate process development of pharmaceutical and biomedical products. Report further covers segments of molecule type which includes monoclonal antibodies, vaccines, recombinant insulin, and human growth hormones etc. The monoclonal antibodies are the largest molecule type segment and had accounted for the largest market revenue share in 2016. The key factor driving the segment growth is the increased adoption of targeted immunotherapy and the increasing number of therapeutic monoclonal antibodies approved by U.S. FDA . Report further covers segments of process type; the market is segmented into upstream processing and downstream processing. The downstream processing is the leading segment and had accounted for largest market revenue share in 2016 due to the increasing demand of purified biosimilars, whereas the end user includes contract manufacturing organizations and biopharmaceutical manufacturers.